Mesenchymal Stem Cell Transfer Suppresses Airway Remodeling in a Toluene Diisocyanate-Induced Murine Asthma Model

다국어 초록 (Multilingual Abstract)

Purpose: Severe asthma is characterized by high medication requirements to maintain good disease control or by persistent symptoms despite high medication use. The transfer of bone marrow-derived mesenchymal stem cells (BMDMSCs) to the injured lungs is a possible treatment for severe asthma. This study investigated the therapeutic effects of BMDMSCs in airway remodeling and inflammation in an experimental toluene diisocyanate (TDI)-induced asthma animal model of severe asthma. Methods: BMDMSCs were transferred into rats after TDI inhalation. Bronchoalveolar lavage (BAL) cell profiles, histological changes including an inflammatory index and goblet cell hyperplasia, and the airway response to methacholine using plethysmography were analyzed. Smooth muscle actin (SMA) and proliferating cell nuclear antigen (PCNA) protein expression were observed in lung tissue using immunohistochemical staining. The collagen content was measured in lung tissue sections and lung extracts using Masson’s trichrome staining and an immunoassay kit. Results: The numbers of inflammatory cells in BAL fluid, histological inflammatory index, airway response to methacholine, number of goblet cells, and amount of collagen were increased in TDI-treated rats compared with sham rats (P=0.05–0.002). BMDMSC transfer significantly reduced the TDI-induced increase in the inflammatory index and numbers of eosinophils and neutrophils in BAL fluid to levels seen in sham-treated rats (P<0.05). BMDMSC transfer significantly reduced the number of goblet cells, collagen deposition, and immune staining for SMA and PCNA with concomitant normalization of the airway response to methacholine. Conclusions: The systemic transfer of BMDMSCs effectively reduced experimental TDI-induced airway inflammation and remodeling and airway hyperreactivity.

참고문헌 (Reference)

1 ten Brinke A, "“Refractory” eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids" 170 : 601-605, 2004

2 "Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions" American Thoracic Society 2341-2351, 2000

3 Xu J, "Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice" 293 : L131-L141, 2007

4 Chan-Yeung M, "Occupational asthma" 98 : 148S-161S, 1990

5 Hamelmann E, "Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography" 156 : 766-775, 1997

6 Krause DS, "Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell" 105 : 369-377, 2001

7 Lee SH, "Modulation of cytokine and nitric oxide by mesenchymal stem cell transfer in lung injury/fibrosis." 11 : 16-, 2010

8 Deans RJ, "Mesenchymal stem cells: biology and potential clinical uses" 28 : 875-884, 2000

9 Ortiz LA, "Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects" 100 : 8407-8411, 2003

10 Pereira RF, "Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta" 95 : 1142-1147, 1998

11 Choi JM, "Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation" 12 (12): 574-579, 2006

12 Anjos-Afonso F, "In vivo contribution of murine mesenchymal stem cells into multiple cell-types under minimal damage conditions" 117 : 5655-5664, 2004

13 Bateman ED, "Global strategy for asthma management and prevention: GINA executive summary" 31 : 143-178, 2008

14 Shin YS, "Gelfand EW. Understanding asthma using animal models" 1 : 10-18, 2009

15 Mealey FH, "Difficult-to-control asthma in adults" 120 : 760-763, 2007

16 Park SW, "Differences in radiological/HRCT findings in eosinophilic bronchitis and asthma: implication for bronchial responsiveness" B M J PUBLISHING GROUP 61 : 41-47, 2006

17 Pepe C, "Differences in airway remodeling between subjects with severe and moderate asthma" 116 : 544-549, 2005

18 Thomas M, "Cost effectiveness of asthma management strategies" 20 : 789-, 2002

19 Sont JK, "Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group" 159 : 1043-1051, 1999

20 Bruder SP, "Bone regeneration by implantation of purified, culture-expanded human mesenchymal stem cells" 16 : 155-162, 1998

21 Yamada M, "Bone marrow-derived progenitor cells are important for lung repair after lipopolysaccharide-induced lung injury" 172 : 1266-1272, 2004

22 Rojas M, "Bone marrow-derived mesenchymal stem cells in repair of the injured lung" 33 : 145-152, 2005

23 Ahn MH, "Asp-Tyr-Leu-Lys tetrapeptide inhibits airway inflammation in toluene-2,4-diisocyanate-induced asthma mice" BLACKWELL PUBLISHING 38 : 1025-1032, 2008

24 Benayoun L, "Airway structural alterations selectively associated with severe asthma" 167 : 1360-1368, 2003

25 Vignola AM, "Airway remodeling in asthma" 123 : 417S-422S, 2003

26 Boulet LP, "Airway hyperresponsiveness, inflammation, and subepithelial collagen deposition in recently diagnosed versus long-standing mild asthma. Influence of inhaled corticosteroids" 162 : 1308-1313, 2000

27 Lange P, "A 15-year follow-up study of ventilatory function in adults with asthma" 339 : 1194-1200, 1998